Tag: Cassava Sciences (SAVA)

Why Cassava Sciences Stock Opened Down Today. See Also: The Mirati Therapeutics and MD Anderson Collaboration

Cassava Sciences Inc Opened Down Today Cassava Sciences, Inc. (SAVA) - a clinical-stage biotech firm focused on the treatment of Alzheimer’s disease, announced that it has entered into a definitive agreement with several healthcare-focused, and other institutional investors, for the purchase of 4,081,633 shares of its common stock at a purchase price of $49.00 per share for . . . This content is for paid subscribers. …

Cassava Sciences: Significant Program Progress and its Expected Milestones for 2021

Cassava Sciences 2021 Focus and Momentum Cassava Sciences (SAVA) President & CEO, Remi Barbier, informed that the firm has started 2021 with tremendous momentum led by results of a 6-month interim analysis from an open-label study of simufilam, Cassava’s drug candidate for Alzheimer’s disease. Mr. Barbier expressed his belief that the rest of the year may . . . This content is for paid subscribers. …

Cassava Sciences Product, Simufilam, Improved the Cognition and Behavior of Alzheimer’s Patients Following Six Months of Treatment

Cassava Sciences Announced Simufilam Results for Alzheimer's Cassava Sciences (SAVA) announced impressive results of an interim analysis from an open-label study of simufilam, a drug candidate for the treatment of Alzheimer’s disease. Simufilam improved both patients’ cognition and behavior scores following six months of treatment. There were no safety issues. In a clinical study funded by the National . . . This content is for …

Cassava Sciences, Moderna and Sorrento Therapeutics All Have News

News from Cassava Sciences, Moderna and Sorrento Therapeutics  Cassava Sciences  Cassava Sciences (SAVA) announced that clinical results of its Phase 2b study of sumifilam have been selected as a late-breaking oral presentation by the 13th international conference on Clinical Trials on Alzheimer’s Disease (CTAD). What is CTAD? CTAD is a prestigious annual conference focused on Alzheimer’s . . . This content is for paid subscribers. …

Cassava Sciences Promising and Encouraging Results of Its Alzheimer’s Disease Product Sumifilam

Cassava Sciences Study Results of Sumifilam for Alzheimer's Disease Prohost is happy to inform our subscribers that our positive opinion about Cassava Sciences' product created and developed for Alzheimer’s disease happens to be right. Cassava Sciences (SAVA) announced today the final results of a Phase 2b study with its lead drug candidate, sumifilam, in Alzheimer’s disease. The results . . . This content is for paid …

Are We Saying Goodbye to Common Sense?

Prohost Letter #441 Biotechnology Companies’ Evaluations Are We Saying Goodbye to Common Sense? The SARS-CoV-2 Vaccines It is said that the difference between the SARS-CoV-2 coronavirus (COVID-19), which is causing the pandemic around the world we are currently suffering from, and other coronaviruses like SARS and/or MERS is that SARS-CoV-2 ability to replicate in the human bodies' respiratory system’s upper airways more than the others. …

Questions & Answers

The Week in Review #51 Questions & Answers About CytomX Q: Is there any reason for the CytomX stock selloff that occurred in early May? In order to answer this question we need to explain CytomX’s (CTMX) Probody therapeutics. These novel treatments are designed to remain inactive until they are activated only . . . This content is for paid subscribers. Please click here to subscribe …
Can Cassava Sciences Product PTI-125 Beat Alzheimer’s Disease?

Can Cassava Sciences Product PTI-125 Beat Alzheimer’s Disease?

Cassava Sciences Stock is Rallying Cassava Sciences (SAVA) stock closed on Friday, December 27, 2019 at $5.21, reaching a 52-week high. Today, December 30, 2019 the stock is jumping higher, trading now at $6.40, UP $1.19 despite the underperforming market today. The reason for investors’ rush to buy the stock is due to the good news from a Phase 2 trial of Cassava’s Alzheimer Disease …

Cassava Sciences: More Positive News in Alzheimer’s Disease

Cassava Sciences: PTI-125 for Alzheimer's Disease Cassava Sciences (SAVA), a clinical-stage biopharmaceutical company focused on Alzheimer’s disease, announced additional clinical data from a Phase 2a study of PTI-125, its investigational drug candidate for Alzheimer’s disease. The new data were presented by the firm’s scientists during a late-breaking oral presentation at the 12thInternational Conference . . . This content is for paid subscribers. Please click here to subscribe …